Netherlands' Sick Funds Control Proposal
Dutch Health Minister Els Borst has proposed to parliament a scheme toplace the control of the sick funds with an institute which would be completely independent of the Sick Fund Council, the main advisory body to the Ministry of Health.
Under her proposal, a number of laws would be adjusted, but the funds themselves would remain responsible for carrying out additional responsibilities.
The Minister's proposal comes in response to criticism of control of the funds (Marketletter April 14), including two reports from the General Accounts Office which also condemned the extra fees imposed on insured people aged over 65. The Office says that supervision of the funds is obsolete, and that the Council's powers are insufficient to exercise adequate control over private insurers which have merged with funds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze